TY - JOUR AU - Parker, C. AU - Gillessen, S. AU - Heidenreich, A. AU - Horwich, A. AU - Committee, E. G. PY - 2015 DA - 2015// TI - Cancer of the prostate: ESMO clinical practice guidelines for diagnosis, treatment and follow-up JO - Ann Oncol VL - 26 UR - https://doi.org/10.1093/annonc/mdv222 DO - 10.1093/annonc/mdv222 ID - Parker2015 ER - TY - JOUR AU - Bray, F. AU - Ferlay, J. AU - Soerjomataram, I. AU - Siegel, R. L. AU - Torre, L. A. AU - Jemal, A. PY - 2018 DA - 2018// TI - Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries JO - CA Cancer J Clin VL - 68 ID - Bray2018 ER - TY - JOUR AU - Roviello, G. AU - Sigala, S. AU - Sandhu, S. AU - Bonetta, A. AU - Cappelletti, M. R. AU - Zanotti, L. PY - 2016 DA - 2016// TI - Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: a literature based meta-analysis of randomized trials JO - Eur J Cancer VL - 61 UR - https://doi.org/10.1016/j.ejca.2016.04.002 DO - 10.1016/j.ejca.2016.04.002 ID - Roviello2016 ER - TY - JOUR AU - Kyriakopoulos, C. E. AU - Chen, Y. H. AU - Carducci, M. A. AU - Liu, G. AU - Jarrard, D. F. AU - Hahn, N. M. PY - 2018 DA - 2018// TI - Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2017.75.3657 DO - 10.1200/JCO.2017.75.3657 ID - Kyriakopoulos2018 ER - TY - JOUR AU - Phi, L. T. H. AU - Sari, I. N. AU - Yang, Y. G. AU - Lee, S. H. AU - Jun, N. AU - Kim, K. S. PY - 2018 DA - 2018// TI - Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment JO - Stem Cells Int VL - 2018 UR - https://doi.org/10.1155/2018/5416923 DO - 10.1155/2018/5416923 ID - Phi2018 ER - TY - JOUR AU - Cazet, A. S. AU - Hui, M. N. AU - Elsworth, B. L. AU - Wu, S. Z. AU - Roden, D. AU - Chan, C. L. PY - 2018 DA - 2018// TI - Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer JO - Nat Commun VL - 9 UR - https://doi.org/10.1038/s41467-018-05220-6 DO - 10.1038/s41467-018-05220-6 ID - Cazet2018 ER - TY - JOUR AU - Maitland, N. J. AU - Collins, A. PY - 2005 DA - 2005// TI - A tumour stem cell hypothesis for the origins of prostate cancer JO - BJU Int VL - 96 UR - https://doi.org/10.1111/j.1464-410X.2005.05744.x DO - 10.1111/j.1464-410X.2005.05744.x ID - Maitland2005 ER - TY - JOUR AU - Libby, C. J. AU - McConathy, J. AU - Darley-Usmar, V. AU - Hjelmeland, A. B. PY - 2020 DA - 2020// TI - The role of metabolic plasticity in blood and brain stem cell pathophysiology JO - Cancer Res VL - 80 UR - https://doi.org/10.1158/0008-5472.CAN-19-1169 DO - 10.1158/0008-5472.CAN-19-1169 ID - Libby2020 ER - TY - STD TI - Roca MS, Di Gennaro E, Budillon A. Implication for cancer stem cells in solid cancer chemo-resistance: promising therapeutic strategies based on the use of HDAC inhibitors. J Clin Med. 2019;8(7):912. ID - ref9 ER - TY - STD TI - Frame FM, Maitland NJ. Epigenetic control of gene expression in the Normal and malignant human prostate: a rapid response which promotes therapeutic resistance. Int J Mol Sci. 2019;20(10):2437. ID - ref10 ER - TY - JOUR AU - Pelton, K. AU - Freeman, M. R. AU - Solomon, K. R. PY - 2012 DA - 2012// TI - Cholesterol and prostate cancer JO - Curr Opin Pharmacol VL - 12 UR - https://doi.org/10.1016/j.coph.2012.07.006 DO - 10.1016/j.coph.2012.07.006 ID - Pelton2012 ER - TY - JOUR AU - Mullen, P. J. AU - Yu, R. AU - Longo, J. AU - Archer, M. C. AU - Penn, L. Z. PY - 2016 DA - 2016// TI - The interplay between cell signalling and the mevalonate pathway in cancer JO - Nat Rev Cancer VL - 16 UR - https://doi.org/10.1038/nrc.2016.76 DO - 10.1038/nrc.2016.76 ID - Mullen2016 ER - TY - JOUR AU - Iannelli, F. AU - Lombardi, R. AU - Milone, M. R. AU - Pucci, B. AU - Rienzo, S. AU - Budillon, A. PY - 2018 DA - 2018// TI - Targeting Mevalonate pathway in cancer treatment: repurposing of statins JO - Recent Pat Anticancer Drug Discov VL - 13 UR - https://doi.org/10.2174/1574892812666171129141211 DO - 10.2174/1574892812666171129141211 ID - Iannelli2018 ER - TY - JOUR AU - Lacher, S. M. AU - Bruttger, J. AU - Kalt, B. AU - Berthelet, J. AU - Rajalingam, K. AU - Wortge, S. PY - 2017 DA - 2017// TI - HMG-CoA reductase promotes protein prenylation and therefore is indispensible for T-cell survival JO - Cell Death Dis VL - 8 UR - https://doi.org/10.1038/cddis.2017.221 DO - 10.1038/cddis.2017.221 ID - Lacher2017 ER - TY - JOUR AU - Allott, E. H. AU - Farnan, L. AU - Steck, S. E. AU - Arab, L. AU - Su, L. J. AU - Mishel, M. PY - 2016 DA - 2016// TI - Statin use and prostate cancer aggressiveness: results from the population-based North Carolina-Louisiana prostate cancer project JO - Cancer Epidemiol Biomarkers Prev VL - 25 UR - https://doi.org/10.1158/1055-9965.EPI-15-0631 DO - 10.1158/1055-9965.EPI-15-0631 ID - Allott2016 ER - TY - JOUR AU - Alfaqih, M. A. AU - Allott, E. H. AU - Hamilton, R. J. AU - Freeman, M. R. AU - Freedland, S. J. PY - 2017 DA - 2017// TI - The current evidence on statin use and prostate cancer prevention: are we there yet? JO - Nat Rev Urol VL - 14 UR - https://doi.org/10.1038/nrurol.2016.199 DO - 10.1038/nrurol.2016.199 ID - Alfaqih2017 ER - TY - JOUR AU - Schweizer, M. T. AU - Yu, E. Y. PY - 2016 DA - 2016// TI - Targeting intratumoral androgens: statins and beyond JO - Ther Adv Med Oncol VL - 8 UR - https://doi.org/10.1177/1758834016647962 DO - 10.1177/1758834016647962 ID - Schweizer2016 ER - TY - JOUR AU - Huang, B. AU - Song, B. L. AU - Xu, C. PY - 2020 DA - 2020// TI - Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities JO - Nat Metab VL - 2 UR - https://doi.org/10.1038/s42255-020-0174-0 DO - 10.1038/s42255-020-0174-0 ID - Huang2020 ER - TY - JOUR AU - Kong, Y. AU - Cheng, L. AU - Mao, F. AU - Zhang, Z. AU - Zhang, Y. AU - Farah, E. PY - 2018 DA - 2018// TI - Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC) JO - J Biol Chem VL - 293 UR - https://doi.org/10.1074/jbc.RA118.004442 DO - 10.1074/jbc.RA118.004442 ID - Kong2018 ER - TY - JOUR AU - Chen, X. AU - Liu, Y. AU - Wu, J. AU - Huang, H. AU - Du, Z. AU - Zhang, K. PY - 2016 DA - 2016// TI - Mechanistic study of inhibitory effects of atorvastatin and Docetaxel in combination on prostate cancer JO - Cancer Genomics Proteomics VL - 13 ID - Chen2016 ER - TY - JOUR AU - Bruzzese, F. AU - Rocco, M. AU - Castelli, S. AU - Gennaro, E. AU - Desideri, A. AU - Budillon, A. PY - 2009 DA - 2009// TI - Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis JO - Mol Cancer Ther VL - 8 UR - https://doi.org/10.1158/1535-7163.MCT-09-0254 DO - 10.1158/1535-7163.MCT-09-0254 ID - Bruzzese2009 ER - TY - JOUR AU - Gennaro, E. AU - Piro, G. AU - Chianese, M. I. AU - Franco, R. AU - Cintio, A. AU - Moccia, T. PY - 2010 DA - 2010// TI - Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase JO - Br J Cancer VL - 103 UR - https://doi.org/10.1038/sj.bjc.6605969 DO - 10.1038/sj.bjc.6605969 ID - Gennaro2010 ER - TY - JOUR AU - Budillon, A. AU - Gennaro, E. AU - Bruzzese, F. AU - Rocco, M. AU - Manzo, G. AU - Caraglia, M. PY - 2007 DA - 2007// TI - Histone deacetylase inhibitors: a new wave of molecular targeted anticancer agents JO - Recent Pat Anticancer Drug Discov VL - 2 UR - https://doi.org/10.2174/157489207780832450 DO - 10.2174/157489207780832450 ID - Budillon2007 ER - TY - JOUR AU - Piro, G. AU - Roca, M. S. AU - Bruzzese, F. AU - Carbone, C. AU - Iannelli, F. AU - Leone, A. PY - 2019 DA - 2019// TI - Vorinostat potentiates 5-fluorouracil/Cisplatin combination by inhibiting chemotherapy-induced EGFR nuclear translocation and increasing Cisplatin uptake JO - Mol Cancer Ther VL - 18 UR - https://doi.org/10.1158/1535-7163.MCT-18-1117 DO - 10.1158/1535-7163.MCT-18-1117 ID - Piro2019 ER - TY - JOUR AU - Mann, B. S. AU - Johnson, J. R. AU - Cohen, M. H. AU - Justice, R. AU - Pazdur, R. PY - 2007 DA - 2007// TI - FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma JO - Oncologist. VL - 12 UR - https://doi.org/10.1634/theoncologist.12-10-1247 DO - 10.1634/theoncologist.12-10-1247 ID - Mann2007 ER - TY - JOUR AU - Grant, C. AU - Rahman, F. AU - Piekarz, R. AU - Peer, C. AU - Frye, R. AU - Robey, R. W. PY - 2010 DA - 2010// TI - Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors JO - Expert Rev Anticancer Ther VL - 10 UR - https://doi.org/10.1586/era.10.88 DO - 10.1586/era.10.88 ID - Grant2010 ER - TY - JOUR AU - Sawas, A. AU - Radeski, D. AU - O'Connor, O. A. PY - 2015 DA - 2015// TI - Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review JO - Ther Adv Hematol VL - 6 UR - https://doi.org/10.1177/2040620715592567 DO - 10.1177/2040620715592567 ID - Sawas2015 ER - TY - JOUR AU - Moore, D. PY - 2016 DA - 2016// TI - Panobinostat (Farydak): a novel option for the treatment of relapsed or relapsed and refractory multiple myeloma JO - P T VL - 41 ID - Moore2016 ER - TY - JOUR AU - Terranova-Barberio, M. AU - Roca, M. S. AU - Zotti, A. I. AU - Leone, A. AU - Bruzzese, F. AU - Vitagliano, C. PY - 2016 DA - 2016// TI - Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression JO - Oncotarget. VL - 7 UR - https://doi.org/10.18632/oncotarget.6802 DO - 10.18632/oncotarget.6802 ID - Terranova-Barberio2016 ER - TY - STD TI - Salem O, Hansen CG. The hippo pathway in prostate cancer. Cells. 2019;8(4):370. ID - ref30 ER - TY - JOUR AU - Bruzzese, F. AU - Pucci, B. AU - Milone, M. R. AU - Ciardiello, C. AU - Franco, R. AU - Chianese, M. I. PY - 2013 DA - 2013// TI - Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways JO - Cell Death Dis VL - 4 UR - https://doi.org/10.1038/cddis.2013.406 DO - 10.1038/cddis.2013.406 ID - Bruzzese2013 ER - TY - JOUR AU - Terranova-Barberio, M. AU - Pecori, B. AU - Roca, M. S. AU - Imbimbo, S. AU - Bruzzese, F. AU - Leone, A. PY - 2017 DA - 2017// TI - Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53 JO - J Exp Clin Cancer Res VL - 36 UR - https://doi.org/10.1186/s13046-017-0647-5 DO - 10.1186/s13046-017-0647-5 ID - Terranova-Barberio2017 ER - TY - JOUR AU - Baghirova, S. AU - Hughes, B. G. AU - Hendzel, M. J. AU - Schulz, R. PY - 2015 DA - 2015// TI - Sequential fractionation and isolation of subcellular proteins from tissue or cultured cells JO - MethodsX. VL - 2 UR - https://doi.org/10.1016/j.mex.2015.11.001 DO - 10.1016/j.mex.2015.11.001 ID - Baghirova2015 ER - TY - JOUR AU - Ciardiello, C. AU - Roca, M. S. AU - Noto, A. AU - Bruzzese, F. AU - Moccia, T. AU - Vitagliano, C. PY - 2016 DA - 2016// TI - Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression JO - Oncotarget. VL - 7 UR - https://doi.org/10.18632/oncotarget.7195 DO - 10.18632/oncotarget.7195 ID - Ciardiello2016 ER - TY - JOUR AU - Noto, A. AU - Vitis, C. AU - Pisanu, M. E. AU - Roscilli, G. AU - Ricci, G. AU - Catizone, A. PY - 2017 DA - 2017// TI - Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ JO - Oncogene. VL - 36 UR - https://doi.org/10.1038/onc.2017.212 DO - 10.1038/onc.2017.212 ID - Noto2017 ER - TY - JOUR AU - Ruocco, N. AU - Annunziata, C. AU - Ianora, A. AU - Libralato, G. AU - Manfra, L. AU - Costantini, S. PY - 2019 DA - 2019// TI - Toxicity of diatom-derived polyunsaturated aldehyde mixtures on sea urchin Paracentrotus lividus development JO - Sci Rep VL - 9 UR - https://doi.org/10.1038/s41598-018-37546-y DO - 10.1038/s41598-018-37546-y ID - Ruocco2019 ER - TY - JOUR AU - Xia, J. AU - Sinelnikov, I. V. AU - Han, B. AU - Wishart, D. S. PY - 2015 DA - 2015// TI - MetaboAnalyst 3.0--making metabolomics more meaningful JO - Nucleic Acids Res VL - 43 UR - https://doi.org/10.1093/nar/gkv380 DO - 10.1093/nar/gkv380 ID - Xia2015 ER - TY - JOUR AU - Colak, S. AU - Zimberlin, C. D. AU - Fessler, E. AU - Hogdal, L. AU - Prasetyanti, P. R. AU - Grandela, C. M. PY - 2014 DA - 2014// TI - Decreased mitochondrial priming determines chemoresistance of colon cancer stem cells JO - Cell Death Differ VL - 21 UR - https://doi.org/10.1038/cdd.2014.37 DO - 10.1038/cdd.2014.37 ID - Colak2014 ER - TY - JOUR AU - Milone, M. R. AU - Pucci, B. AU - Bruzzese, F. AU - Carbone, C. AU - Piro, G. AU - Costantini, S. PY - 2013 DA - 2013// TI - Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells JO - Cell Death Dis VL - 4 UR - https://doi.org/10.1038/cddis.2013.165 DO - 10.1038/cddis.2013.165 ID - Milone2013 ER - TY - JOUR AU - Costa, C. D. AU - Justo, A. A. AU - Kobayashi, P. E. AU - Story, M. M. AU - Palmieri, C. AU - Laufer Amorim, R. PY - 2019 DA - 2019// TI - Characterization of OCT3/4, nestin, NANOG, CD44 and CD24 as stem cell markers in canine prostate cancer JO - Int J Biochem Cell Biol VL - 108 UR - https://doi.org/10.1016/j.biocel.2019.01.002 DO - 10.1016/j.biocel.2019.01.002 ID - Costa2019 ER - TY - JOUR AU - Chen, F. AU - Chen, X. AU - Ren, Y. AU - Weng, G. AU - Keng, P. C. AU - Chen, Y. PY - 2019 DA - 2019// TI - Radiation-induced glucocorticoid receptor promotes CD44+ prostate cancer stem cell growth through activation of SGK1-Wnt/beta-catenin signaling JO - J Mol Med (Berl) VL - 97 UR - https://doi.org/10.1007/s00109-019-01807-8 DO - 10.1007/s00109-019-01807-8 ID - Chen2019 ER - TY - JOUR AU - Kalantari, E. AU - Asgari, M. AU - Nikpanah, S. AU - Salarieh, N. AU - Asadi Lari, M. H. AU - Madjd, Z. PY - 2017 DA - 2017// TI - Co-expression of putative cancer stem cell markers CD44 and CD133 in prostate carcinomas JO - Pathol Oncol Res VL - 23 UR - https://doi.org/10.1007/s12253-016-0169-z DO - 10.1007/s12253-016-0169-z ID - Kalantari2017 ER - TY - JOUR AU - Wei, M. AU - Mao, S. AU - Lu, G. AU - Li, L. AU - Lan, X. AU - Huang, Z. PY - 2018 DA - 2018// TI - Valproic acid sensitizes metformin-resistant human renal cell carcinoma cells by upregulating H3 acetylation and EMT reversal JO - BMC Cancer VL - 18 UR - https://doi.org/10.1186/s12885-018-4344-3 DO - 10.1186/s12885-018-4344-3 ID - Wei2018 ER - TY - JOUR AU - Babcook, M. A. AU - Shukla, S. AU - Fu, P. AU - Vazquez, E. J. AU - Puchowicz, M. A. AU - Molter, J. P. PY - 2014 DA - 2014// TI - Synergistic simvastatin and metformin combination chemotherapy for osseous metastatic castration-resistant prostate cancer JO - Mol Cancer Ther VL - 13 UR - https://doi.org/10.1158/1535-7163.MCT-14-0451 DO - 10.1158/1535-7163.MCT-14-0451 ID - Babcook2014 ER - TY - JOUR AU - Gonneaud, A. AU - Turgeon, N. AU - Boisvert, F. M. AU - Boudreau, F. AU - Asselin, C. PY - 2015 DA - 2015// TI - Loss of histone deacetylase Hdac1 disrupts metabolic processes in intestinal epithelial cells JO - FEBS Lett VL - 589 UR - https://doi.org/10.1016/j.febslet.2015.08.009 DO - 10.1016/j.febslet.2015.08.009 ID - Gonneaud2015 ER - TY - JOUR AU - Sorrentino, G. AU - Ruggeri, N. AU - Specchia, V. AU - Cordenonsi, M. AU - Mano, M. AU - Dupont, S. PY - 2014 DA - 2014// TI - Metabolic control of YAP and TAZ by the mevalonate pathway JO - Nat Cell Biol VL - 16 UR - https://doi.org/10.1038/ncb2936 DO - 10.1038/ncb2936 ID - Sorrentino2014 ER - TY - STD TI - Jiang Z, Chen X, Chen K, Sun L, Gao L, Zhou C, et al. YAP inhibition by resveratrol via activation of AMPK enhances the sensitivity of pancreatic cancer cells to gemcitabine. Nutrients. 2016;8(10):546. ID - ref47 ER - TY - JOUR AU - DeRan, M. AU - Yang, J. AU - Shen, C. H. AU - Peters, E. C. AU - Fitamant, J. AU - Chan, P. PY - 2014 DA - 2014// TI - Energy stress regulates hippo-YAP signaling involving AMPK-mediated regulation of angiomotin-like 1 protein JO - Cell Rep VL - 9 UR - https://doi.org/10.1016/j.celrep.2014.09.036 DO - 10.1016/j.celrep.2014.09.036 ID - DeRan2014 ER - TY - JOUR AU - Philippe, C. AU - Pinson, B. AU - Dompierre, J. AU - Pantesco, V. AU - Viollet, B. AU - Daignan-Fornier, B. PY - 2018 DA - 2018// TI - AICAR Antiproliferative properties involve the AMPK-independent activation of the tumor suppressors LATS 1 and 2 JO - Neoplasia. VL - 20 UR - https://doi.org/10.1016/j.neo.2018.03.006 DO - 10.1016/j.neo.2018.03.006 ID - Philippe2018 ER - TY - JOUR AU - Lian, I. AU - Kim, J. AU - Okazawa, H. AU - Zhao, J. AU - Zhao, B. AU - Yu, J. PY - 2010 DA - 2010// TI - The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation JO - Genes Dev VL - 24 UR - https://doi.org/10.1101/gad.1903310 DO - 10.1101/gad.1903310 ID - Lian2010 ER - TY - JOUR AU - Yan, B. AU - Jiang, Z. AU - Cheng, L. AU - Chen, K. AU - Zhou, C. AU - Sun, L. PY - 2018 DA - 2018// TI - Paracrine HGF/c-MET enhances the stem cell-like potential and glycolysis of pancreatic cancer cells via activation of YAP/HIF-1alpha JO - Exp Cell Res VL - 371 UR - https://doi.org/10.1016/j.yexcr.2018.07.041 DO - 10.1016/j.yexcr.2018.07.041 ID - Yan2018 ER - TY - STD TI - McKee C, Brown C, Chaudhry GR. Self-assembling scaffolds supported long-term growth of human primed embryonic stem cells and Upregulated Core and naive pluripotent markers. Cells. 2019;8(12):1650. ID - ref52 ER - TY - JOUR AU - Wu, J. D. AU - Haugk, K. AU - Coleman, I. AU - Woodke, L. AU - Vessella, R. AU - Nelson, P. PY - 2006 DA - 2006// TI - Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors JO - Clin Cancer Res VL - 12 UR - https://doi.org/10.1158/1078-0432.CCR-06-0443 DO - 10.1158/1078-0432.CCR-06-0443 ID - Wu2006 ER - TY - JOUR AU - Stine, J. E. AU - Guo, H. AU - Sheng, X. AU - Han, X. AU - Schointuch, M. N. AU - Gilliam, T. P. PY - 2016 DA - 2016// TI - The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer JO - Oncotarget. VL - 7 UR - https://doi.org/10.18632/oncotarget.5834 DO - 10.18632/oncotarget.5834 ID - Stine2016 ER - TY - JOUR AU - Harada, M. AU - Iwata, C. AU - Saito, H. AU - Ishii, K. AU - Hayashi, T. AU - Yashiro, M. PY - 2012 DA - 2012// TI - NC-6301, a polymeric micelle rationally optimized for effective release of docetaxel, is potent but is less toxic than native docetaxel in vivo JO - Int J Nanomedicine VL - 7 ID - Harada2012 ER - TY - JOUR AU - Jiang, S. Y. AU - Li, H. AU - Tang, J. J. AU - Wang, J. AU - Luo, J. AU - Liu, B. PY - 2018 DA - 2018// TI - Discovery of a potent HMG-CoA reductase degrader that eliminates statin-induced reductase accumulation and lowers cholesterol JO - Nat Commun VL - 9 UR - https://doi.org/10.1038/s41467-018-07590-3 DO - 10.1038/s41467-018-07590-3 ID - Jiang2018 ER - TY - JOUR AU - Zhang, Z. AU - Cheng, L. AU - Li, J. AU - Farah, E. AU - Atallah, N. M. AU - Pascuzzi, P. E. PY - 2018 DA - 2018// TI - Inhibition of the Wnt/beta-catenin pathway overcomes resistance to Enzalutamide in castration-resistant prostate cancer JO - Cancer Res VL - 78 ID - Zhang2018 ER - TY - JOUR AU - Chen, C. C. AU - Hsieh, T. F. AU - Huang, C. P. AU - Yu, A. L. AU - Chang, W. L. AU - Shyr, C. R. PY - 2016 DA - 2016// TI - Androgen receptor expands the population of cancer stem cells in upper urinary tract urothelial cell carcinoma cells JO - Am J Cancer Res VL - 6 ID - Chen2016 ER - TY - JOUR AU - Portillo-Lara, R. AU - Alvarez, M. M. PY - 2015 DA - 2015// TI - Enrichment of the cancer stem phenotype in sphere cultures of prostate cancer cell lines occurs through activation of developmental pathways mediated by the transcriptional regulator DeltaNp63alpha JO - PLoS One VL - 10 UR - https://doi.org/10.1371/journal.pone.0130118 DO - 10.1371/journal.pone.0130118 ID - Portillo-Lara2015 ER - TY - JOUR AU - Santinon, G. AU - Pocaterra, A. AU - Dupont, S. PY - 2016 DA - 2016// TI - Control of YAP/TAZ activity by metabolic and nutrient-sensing pathways JO - Trends Cell Biol VL - 26 UR - https://doi.org/10.1016/j.tcb.2015.11.004 DO - 10.1016/j.tcb.2015.11.004 ID - Santinon2016 ER - TY - JOUR AU - Mancini, R. AU - Noto, A. AU - Pisanu, M. E. AU - Vitis, C. AU - Maugeri-Sacca, M. AU - Ciliberto, G. PY - 2018 DA - 2018// TI - Metabolic features of cancer stem cells: the emerging role of lipid metabolism JO - Oncogene. VL - 37 UR - https://doi.org/10.1038/s41388-018-0141-3 DO - 10.1038/s41388-018-0141-3 ID - Mancini2018 ER - TY - JOUR AU - Zanconato, F. AU - Battilana, G. AU - Forcato, M. AU - Filippi, L. AU - Azzolin, L. AU - Manfrin, A. PY - 2018 DA - 2018// TI - Transcriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4 JO - Nat Med VL - 24 UR - https://doi.org/10.1038/s41591-018-0158-8 DO - 10.1038/s41591-018-0158-8 ID - Zanconato2018 ER - TY - JOUR AU - Jiang, N. AU - Ke, B. AU - Hjort-Jensen, K. AU - Iglesias-Gato, D. AU - Wang, Z. AU - Chang, P. PY - 2017 DA - 2017// TI - YAP1 regulates prostate cancer stem cell-like characteristics to promote castration resistant growth JO - Oncotarget. VL - 8 UR - https://doi.org/10.18632/oncotarget.23014 DO - 10.18632/oncotarget.23014 ID - Jiang2017 ER - TY - STD TI - Lai CJ, Lin CY, Liao WY, Hour TC, Wang HD, Chuu CP. CD44 promotes migration and invasion of Docetaxel-resistant prostate cancer cells likely via induction of hippo-yap signaling. Cells. 2019;8(4):295. ID - ref64 ER - TY - JOUR AU - Zhang, L. AU - Yang, S. AU - Chen, X. AU - Stauffer, S. AU - Yu, F. AU - Lele, S. M. PY - 2015 DA - 2015// TI - The hippo pathway effector YAP regulates motility, invasion, and castration-resistant growth of prostate cancer cells JO - Mol Cell Biol VL - 35 UR - https://doi.org/10.1128/MCB.00102-15 DO - 10.1128/MCB.00102-15 ID - Zhang2015 ER - TY - JOUR AU - Lin, C. J. AU - Lo, U. G. AU - Hsieh, J. T. PY - 2019 DA - 2019// TI - The regulatory pathways leading to stem-like cells underlie prostate cancer progression JO - Asian J Androl VL - 21 UR - https://doi.org/10.4103/aja.aja_72_18 DO - 10.4103/aja.aja_72_18 ID - Lin2019 ER - TY - JOUR AU - Ginestier, C. AU - Monville, F. AU - Wicinski, J. AU - Cabaud, O. AU - Cervera, N. AU - Josselin, E. PY - 2012 DA - 2012// TI - Mevalonate metabolism regulates basal breast cancer stem cells and is a potential therapeutic target JO - Stem Cells VL - 30 UR - https://doi.org/10.1002/stem.1122 DO - 10.1002/stem.1122 ID - Ginestier2012 ER - TY - JOUR AU - Lin, Z. AU - Bishop, K. S. AU - Sutherland, H. AU - Marlow, G. AU - Murray, P. AU - Denny, W. A. PY - 2016 DA - 2016// TI - A quinazoline-based HDAC inhibitor affects gene expression pathways involved in cholesterol biosynthesis and mevalonate in prostate cancer cells JO - Mol Biosyst VL - 12 UR - https://doi.org/10.1039/C5MB00554J DO - 10.1039/C5MB00554J ID - Lin2016 ER - TY - JOUR AU - Karlic, H. AU - Thaler, R. AU - Gerner, C. AU - Grunt, T. AU - Proestling, K. AU - Haider, F. PY - 2015 DA - 2015// TI - Inhibition of the mevalonate pathway affects epigenetic regulation in cancer cells JO - Cancer Genet VL - 208 UR - https://doi.org/10.1016/j.cancergen.2015.03.008 DO - 10.1016/j.cancergen.2015.03.008 ID - Karlic2015 ER - TY - JOUR AU - Sonnemann, J. AU - Bumbul, B. AU - Beck, J. F. PY - 2007 DA - 2007// TI - Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro JO - Mol Cancer Ther VL - 6 UR - https://doi.org/10.1158/1535-7163.MCT-07-0221 DO - 10.1158/1535-7163.MCT-07-0221 ID - Sonnemann2007 ER - TY - JOUR AU - Wei, T. T. AU - Lin, Y. T. AU - Chen, W. S. AU - Luo, P. AU - Lin, Y. C. AU - Shun, C. T. PY - 2016 DA - 2016// TI - Dual targeting of 3-Hydroxy-3-methylglutaryl coenzyme a Reductase and histone Deacetylase as a therapy for colorectal cancer JO - EBioMedicine. VL - 10 UR - https://doi.org/10.1016/j.ebiom.2016.07.019 DO - 10.1016/j.ebiom.2016.07.019 ID - Wei2016 ER - TY - JOUR AU - Chang, Y. L. AU - Huang, L. C. AU - Chen, Y. C. AU - Wang, Y. W. AU - Hueng, D. Y. AU - Huang, S. M. PY - 2017 DA - 2017// TI - The synergistic effects of valproic acid and fluvastatin on apoptosis induction in glioblastoma multiforme cell lines JO - Int J Biochem Cell Biol VL - 92 UR - https://doi.org/10.1016/j.biocel.2017.10.003 DO - 10.1016/j.biocel.2017.10.003 ID - Chang2017 ER - TY - JOUR AU - Kou, X. AU - Yang, Y. AU - Jiang, X. AU - Liu, H. AU - Sun, F. AU - Wang, X. PY - 2017 DA - 2017// TI - Vorinostat and simvastatin have synergistic effects on triple-negative breast cancer cells via abrogating Rab7 prenylation JO - Eur J Pharmacol VL - 813 UR - https://doi.org/10.1016/j.ejphar.2017.08.022 DO - 10.1016/j.ejphar.2017.08.022 ID - Kou2017 ER - TY - JOUR AU - Lin, Z. AU - Zhang, Z. AU - Jiang, X. AU - Kou, X. AU - Bao, Y. AU - Liu, H. PY - 2017 DA - 2017// TI - Mevastatin blockade of autolysosome maturation stimulates LBH589-induced cell death in triple-negative breast cancer cells JO - Oncotarget. VL - 8 UR - https://doi.org/10.18632/oncotarget.14868 DO - 10.18632/oncotarget.14868 ID - Lin2017 ER - TY - JOUR AU - Milone, M. R. AU - Pucci, B. AU - Bifulco, K. AU - Iannelli, F. AU - Lombardi, R. AU - Ciardiello, C. PY - 2015 DA - 2015// TI - Proteomic analysis of zoledronic-acid resistant prostate cancer cells unveils novel pathways characterizing an invasive phenotype JO - Oncotarget. VL - 6 UR - https://doi.org/10.18632/oncotarget.2694 DO - 10.18632/oncotarget.2694 ID - Milone2015 ER - TY - JOUR AU - Salminen, J. K. AU - Tammela, T. L. AU - Auvinen, A. AU - Murtola, T. J. PY - 2016 DA - 2016// TI - Antiepileptic drugs with histone deacetylase inhibition activity and prostate cancer risk: a population-based case-control study JO - Cancer Causes Control VL - 27 UR - https://doi.org/10.1007/s10552-016-0737-2 DO - 10.1007/s10552-016-0737-2 ID - Salminen2016 ER - TY - JOUR AU - Han, H. AU - Yang, B. AU - Nakaoka, H. J. AU - Yang, J. AU - Zhao, Y. AU - Nguyen, K. PY - 2018 DA - 2018// TI - Hippo signaling dysfunction induces cancer cell addiction to YAP JO - Oncogene. VL - 37 UR - https://doi.org/10.1038/s41388-018-0419-5 DO - 10.1038/s41388-018-0419-5 ID - Han2018 ER - TY - JOUR AU - Petrylak, D. P. AU - Tangen, C. M. AU - Hussain, M. H. AU - Lara, P. N. AU - Jones, J. A. AU - Taplin, M. E. PY - 2004 DA - 2004// TI - Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer JO - N Engl J Med VL - 351 UR - https://doi.org/10.1056/NEJMoa041318 DO - 10.1056/NEJMoa041318 ID - Petrylak2004 ER - TY - JOUR AU - Ruggero, K. AU - Farran-Matas, S. AU - Martinez-Tebar, A. AU - Aytes, A. PY - 2018 DA - 2018// TI - Epigenetic regulation in prostate cancer progression JO - Curr Mol Biol Rep VL - 4 UR - https://doi.org/10.1007/s40610-018-0095-9 DO - 10.1007/s40610-018-0095-9 ID - Ruggero2018 ER - TY - JOUR AU - Kaushik, D. AU - Vashistha, V. AU - Isharwal, S. AU - Sediqe, S. A. AU - Lin, M. F. PY - 2015 DA - 2015// TI - Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials JO - Ther Adv Urol VL - 7 UR - https://doi.org/10.1177/1756287215597637 DO - 10.1177/1756287215597637 ID - Kaushik2015 ER - TY - JOUR AU - Avallone, A. AU - Piccirillo, M. C. AU - Delrio, P. AU - Pecori, B. AU - Gennaro, E. AU - Aloj, L. PY - 2014 DA - 2014// TI - Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short radiotherapy--rectum 3rd trial) JO - BMC Cancer VL - 14 UR - https://doi.org/10.1186/1471-2407-14-875 DO - 10.1186/1471-2407-14-875 ID - Avallone2014 ER - TY - JOUR AU - Caponigro, F. AU - Gennaro, E. AU - Ionna, F. AU - Longo, F. AU - Aversa, C. AU - Pavone, E. PY - 2016 DA - 2016// TI - Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of head and neck-V-CHANCE trial JO - BMC Cancer VL - 16 UR - https://doi.org/10.1186/s12885-016-2957-y DO - 10.1186/s12885-016-2957-y ID - Caponigro2016 ER -